Scot has over thirty years of industrial experience in pioneering and commercializing cutting-edge tools for life science research. Scot is a prolific inventor and holds 22 United States Patents for solutions in liquid chromatography, ultraviolet – visible spectrometry, capillary electrophoresis, time-of-flight mass spectrometry, matrix-assisted laser desorption/ionization, protein biochip technology, tandem mass spectrometry, and surface-tethered and free-solution label-free biosensors. He has authored over thirty scientific publications, 6 book chapters, and has over 2,000 citations in the areas of translational medicine, life science research, and technology development. As an entrepreneur, Scot has been in the founding teams of Linear Instruments, Linear Scientific, Biomolecular Separations, and Ciphergen Biosystems. More recently, he founded and launched Molecular Sensing and GenNext Technologies.

Professor Sharp is a world-renowned and internationally recognized expert in HRPF. He has over twenty-one peer-reviewed articles and has presented numerous invited lectures on the subject of biopharmaceutical HRPF. Josh is also an Associate Professor of Pharmacology and Research Professor of the Research Institute of Pharmaceutical Sciences at the University of Mississippi.

Dr. Grant is the Founder and CEO of Lemnos Advisory, LLC, which provides insights into strategic topics and corporate development for operating companies, transaction advisors, investment banks, and venture investors. He also holds various director and advisor positions in technology-intensive startups and non-profit BODs, mentors and judges for venture accelerators, and invests with multiple angel groups.

Previously, Dr. Grant led global strategy and external business development in several 3M divisions within the Healthcare and Industrial Business Groups. He led and participated in 25 acquisitions, divestitures, and minority corporate venture investments. Earlier, he held managerial positions in product and technology development, quality management, strategic marketing, and business management.

Dr. Grant’s earned an MBA from the Carlson School of Management at the University of Minnesota and a PhD from Northwestern University. He is a member of the National Association of Corporate Directors and has earned the NACD Certified Director designation.

David Weber joined the GenNext Technology Board of Directors in July 2025.  David has close to 50 years of commercial experience across the life sciences industry with companies such as Pharmacia Biotech, Amersham Biosciences, GE Healthcare, Chemdex, Stratagene, and Eksigent Technologies. David also served as Executive Vice President and Chief Commercial Officer of Affymetrix prior to its acquisition by Thermo Fisher Scientific, he also held the same role at Maravai LifeSciences through its IPO.

David currently serves as an Executive Advisor to Ampersand Capital Partners and sits on the Board of Directors of  Ampersand portfolio company Leinco Technologies, a specialty manufacturer of discovery research products and a provider of CDMO services. David also is the founder and President of Weber & Associates, a life science consulting firm, and serves as a commercial advisor to several life science tools firms. He also serves on the Board of Directors of SAMPS, a non-profit organization for life science sales and marketing professionals.

David holds a B.S. in Biochemistry from Rutgers University where he was honored as a Henry Rutgers Scholar and member of Phi Beta Kappa.